Cardiovascular Risk and the Use of Biologic Agents in Rheumatoid Arthritis
- 529 Downloads
Although patients with rheumatoid arthritis (RA) are recognized to be disproportionately impacted by cardiovascular disease (CVD), effective approaches of primary and secondary CVD prevention have not been well defined in this population. Given their robust disease-modifying potential and effects on both pro-inflammatory and pro-atherogenic pathways, there has been substantial speculation that biologic treatments may serve as a means of providing highly effective RA disease control while simultaneously reducing CVD risk in this high risk group. In this review, we examine available evidence relevant to the associations of approved biologic treatments with CVD outcomes in the context of RA.
KeywordsCardiovascular disease Myocardial infarction Rheumatoid arthritis Tumor necrosis factor Biologic Atherosclerosis
The view(s) expressed herein are those of the author(s) and do not reflect theofficial policy or position of the Veterans’ Affairs Medical Center.
Compliance with Ethics Guidelines
Conflict of Interest
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 10.Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: A ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 2005;52(8):2293–9.PubMedCrossRefGoogle Scholar
- 21.••Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4):576–82. An observational cohort study examining composite CV outcomes associated with the use of TNF antagonists in RA, with the provision of relative risks adjusted for other treatment exposures.PubMedCrossRefGoogle Scholar
- 43.••Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: Anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(4):522–9. A report of pooled relative risks associated with TNF inhibition in RA for the occurrence of CV outcomes. Although results suggest possible CV protection with anti-TNF in cohort studies, results must be interpreted with caution given evidence of study heterogeneity and possible publication bias.CrossRefGoogle Scholar
- 46.Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375–82.PubMedCrossRefGoogle Scholar
- 47.•Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: A systematic literature review. Rheumatology (Oxford). 2011;50(3):518–31. A review examining associations of TNF inhibition in RA with the occurrence of CV events.CrossRefGoogle Scholar
- 53.•Bili A, Tang X, Pranesh S, et al. Tumor necrosis factor alpha inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(3):355–63. An observational cohort study examining CVD outcomes associated with TNF inhibition in RA compared to CVD outcomes associated with methotrexate and non-methotrexate non-biologic DMARDs.CrossRefGoogle Scholar
- 54.Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: Results from the british society for rheumatology biologics register. Arthritis Rheum. 2007;56(9):2905–12.PubMedPubMedCentralCrossRefGoogle Scholar
- 68.Chung ES, Packer M, Lo KH, et al. Anti-TNF therapy against congestive heart failure investigators. randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107(25):3133–40.PubMedCrossRefGoogle Scholar
- 77.•Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the virginia commonwealth university-anakinra remodeling trial (2) (VCU-ART2) pilot study. Am J Cardiol. 2013;111(10):1394–400. An initial intervention study examining the impact of anakinra on CV outcomes in non-RA patients following myocardial infarction.PubMedPubMedCentralCrossRefGoogle Scholar
- 78.•Van Tassell BW, Arena R, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014;113(2):321–7. A study on effect of anakinra in heart failure.PubMedCrossRefGoogle Scholar
- 89.Mathieu S, Couderc M, Glace B, et al. Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis. Biol. 2013;7:259–64.Google Scholar